Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7283420 |
Synonyms | |
Therapy Description |
RO7283420 is a T-cell receptor-like T-cell engaging bispecific antibody (T-BsAb) that targets a 9-amino acid peptide derived from Wilms tumor 1 (WT1) and CD3 expressed on T-lymphocytes, which potentially leads to a cytotoxic T-lymphocyte response against tumor cells expressing WT1 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7283420 | RO-7283420|RO 7283420|RG6007|RG-6007|RG 6007|HLA-A2-WT1 x CD3 RG6007 | CD3 Antibody 103 | RO7283420 is a T-cell receptor-like T-cell engaging bispecific antibody (T-BsAb) that targets a 9-amino acid peptide derived from Wilms tumor 1 (WT1) and CD3 expressed on T-lymphocytes, which potentially leads to a cytotoxic T-lymphocyte response against tumor cells expressing WT1 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|